Skip to main content
    H

    Heartbeam Inc (BEAT)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $0.36
    -0.04 (-9.23%)

    Market Cap: $25.04M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Heartbeam Inc (BEAT) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Heartbeam (BEAT) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Heartbeam reported EPS of -$0.05, above the -$0.09 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    49%(18/37)
    Avg Surprise
    -6.17%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.09
    Range-$0.10 - -$0.08
    5 analysts
    Revenue Consensus
    $204.00K
    RangeN/A
    5 analysts

    Next Report

    BEAT has an expected report date of Mar 10, 2027.

    BEAT Earnings Call

    The latest BEAT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, BEAT beat 18, missed 13 and matched 6. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 329.41% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.05-$0.09-$0.10 - -$0.08+44.44%BeatN/A31 up, 0 downNov 12, 2026N/A
    Jun 30, 2026-$0.10-$0.10-$0.11 - -$0.080.00%In lineN/A43 up, 0 downAug 13, 2026N/A
    Mar 31, 2026-$0.12-$0.13-$0.14 - -$0.13+7.69%BeatN/A41 up, 1 downMay 13, 2026N/A
    Dec 31, 2025-$0.14-$0.16-$0.16 - -$0.10+9.68%BeatN/A41 up, 0 downMar 12, 2026N/A
    Sep 30, 2025-$0.15-$0.15-$0.16 - -$0.150.00%In lineN/A21 up, 0 downNov 13, 2025N/A
    Jun 30, 2025-$0.15-$0.16N/A+6.25%BeatN/AN/A0 up, 0 downAug 13, 2025N/A
    Mar 31, 2025-$0.18-$0.15N/A-20.00%MissN/AN/A0 up, 0 downMay 13, 2025N/A
    Dec 31, 2024-$0.73-$0.17N/A-329.41%MissN/AN/A0 up, 0 downMar 13, 2025N/A
    Sep 30, 2024-$0.19-$0.17-$0.18 - -$0.17-11.76%MissN/A20 up, 0 downNov 7, 2024N/A
    Jun 30, 2024-$0.19-$0.16-$0.18 - -$0.15-18.75%MissN/A20 up, 0 downAug 14, 2024N/A
    Mar 31, 2024-$0.17-$0.15-$0.15 - -$0.15-13.33%MissN/A10 up, 0 downMay 9, 2024N/A
    Dec 31, 2023-$0.15-$0.13-$0.14 - -$0.12-15.38%MissN/A40 up, 0 downMar 20, 2024N/A
    Sep 30, 2023-$0.13-$0.13-$0.13 - -$0.130.00%In lineN/A30 up, 0 downNov 14, 2023N/A
    Jun 30, 2023-$0.16-$0.20N/A+20.00%BeatN/A20 up, 0 downAug 10, 2023N/A
    Mar 31, 2023-$0.50-$0.33-$0.44 - -$0.18-51.52%MissN/A20 up, 0 downMay 11, 2023N/A
    Dec 31, 2022-$0.45-$0.37-$0.48 - -$0.17-21.62%MissN/A30 up, 0 downMar 16, 2023N/A
    Sep 30, 2022-$0.44-$0.34-$0.34 - -$0.31-29.41%MissN/A20 up, 0 downNov 10, 2022N/A
    Jun 30, 2022-$0.43-$0.27-$0.27 - -$0.27-59.26%MissN/A10 up, 0 downAug 11, 2022N/A
    Mar 31, 2022-$0.27-$0.19-$0.19 - -$0.19-42.11%MissN/A10 up, 0 downMay 12, 2022N/A
    Dec 31, 2021-$0.24-$0.11N/A-118.18%MissN/AN/A0 up, 0 downMar 24, 2022N/A
    Sep 30, 2021-$0.32-$0.32N/A0.00%In line-171.1%N/AN/ANov 17, 2021N/A
    Jun 30, 2021-$0.02N/AN/AN/AN/A-105.7%N/AN/AJul 9, 2021N/A
    Mar 31, 2021-$0.26N/AN/AN/AN/A-156.8%N/AN/AJun 30, 2021N/A
    Dec 31, 2020-$0.06N/AN/AN/AN/A-111.9%N/AN/AFeb 22, 2021N/A
    Sep 30, 2020$0.45$0.38N/A+18.42%Beat-13.5%N/AN/AOct 29, 2020N/A
    Jun 30, 2020$0.35$0.16N/A+118.75%Beat-34.0%N/AN/AJul 30, 2020$99.11M
    Mar 31, 2020$0.45$0.43N/A+4.65%Beat+7.1%N/AN/AMay 6, 2020$113.03M
    Dec 31, 2019$0.48$0.48N/A0.00%In line-14.3%N/AN/AFeb 26, 2020$112.03M
    Sep 30, 2019$0.52$0.50N/A+4.00%Beat-1.9%N/AN/ANov 5, 2019$111.29M
    Jun 30, 2019$0.53$0.45N/A+17.78%Beat+15.2%N/AN/AJul 30, 2019$111.80M
    Mar 31, 2019$0.42$0.41N/A+2.44%Beat+7.7%N/AN/AApr 25, 2019$103.98M
    Dec 31, 2018$0.56$0.43N/A+30.23%Beat+75.0%N/AN/AFeb 21, 2019$103.60M
    Sep 30, 2018$0.53$0.32N/A+65.63%Beat+231.3%N/AN/AOct 30, 2018$100.01M
    Jun 30, 2018$0.46$0.31N/A+48.39%Beat+100.0%N/AN/AJul 25, 2018$101.36M
    Mar 31, 2018$0.39$0.23N/A+69.57%Beat+143.8%N/AN/AApr 25, 2018$94.50M
    Dec 31, 2017$0.32$0.24N/A+33.33%Beat+39.1%N/AN/AFeb 22, 2018$91.74M
    Sep 30, 2017$0.16$0.25N/A-36.00%Miss-23.8%N/AN/ANov 7, 2017$81.02M
    Jun 30, 2017$0.23$0.21N/A+9.52%Beat+15.0%N/AN/AAug 8, 2017$58.13M
    Mar 31, 2017$0.16$0.16N/A0.00%In line-20.0%N/AN/AMay 3, 2017$55.88M
    Dec 31, 2016$0.23$0.18N/A+27.78%Beat+53.3%N/AN/AFeb 22, 2017$53.96M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.62, after -$1.28 the year before. It was $0.84 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.62N/A
    Dec 31, 2024-$1.28N/A
    Dec 31, 2023-$0.94N/A
    Dec 31, 2022-$1.59N/A
    Dec 31, 2021-$0.84-170.0%
    Dec 31, 2020$1.19-38.8%
    Dec 31, 2019$1.95N/A
    Dec 31, 2018$1.94+123.0%
    Dec 31, 2017$0.87N/A
    Dec 31, 2016$0.84N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,800 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,8167
    2026Q2Jun 30, 20267,6488
    2026Q1Mar 31, 20266,7017
    2025Q4Dec 31, 20258,7749
    2025Q3Sep 30, 20255,0666
    2025Q2Jun 30, 20255,4445
    2025Q1Mar 31, 20255,7246
    2024Q4Dec 31, 20244,7973

    2026Q3 Earnings Call

    Opening remarks

    Richard Ferrari Executive Chairman Thank you, and thanks to all of you who have dialed into the conference call. Let me just walk you through the agenda very briefly. We're going to give you the progress on our key strategic initiatives. We'll bring you updates regarding our cardiac platform and our heart attack detection, which is an incredible milestone that we've achieved this particular quarter. And then finally, we'll close out with the financials. Next slide. The progress on the key strategic priorities. I think many of you who have been following the company will remember that in July of this year, we outlined our plan going forward, and we organized the focus on our core strategic priorities, which are shown on this particular slide. That was MI detection, working closely with the FDA, working on reimbursement, enhancing the long-term value of the company through AI and the other technological initiatives, and then on the financial side, cost efficiency and tight controls with respect to running the company. Now, when you look at heart attack detection, I have to say that in the last 90 days, Q3 was a fabulous quarter for achievement, and I think that's a testament to the team we have and the shift to the priorities that I have already mentioned. When you look at those achievements, these milestones are, for a small company, quite significant. Getting Breakthrough Device Designation, something we were really going after and really wanted to count on. And just to give you sort of a reference point, the FDA, on average over the last 5, 6, 7 years, only hands out about 164 of these designations. So it's proof that the technology and the opportunity to enhance patients' lives is significant with respect to HeartBeam. That also enabled us to get enrolled, if you will, into their TAP program. Now, the TAP program is also quite significant because it enables us to have faster turnaround with our communications with the FDA. It also opens up CMS and payers so that we can have discussions with them regarding reimbursement and what needs they need to see in our clinical trial to establish reimbursement. And then I think many of you may know that we had our publication, our presentation at the TCT meeting at the end of October, which again, in our perspective, is the first study—it was 132 patients—to really look at, in an emergency room setting, a comparison between the gold standard of the last 50 years, the 12-lead EKG, and our handheld device for MI detection. And those results, Branislav will touch on a little bit later in this presentation, were significant. I don't know that we've said this before.

    Frequently Asked Questions About BEAT

    When is Heartbeam's next earnings date?

    Heartbeam's next earnings report is expected for Mar 10, 2027.

    Did BEAT beat earnings estimates last quarter?

    Yes. Heartbeam reported EPS of -$0.05 for the quarter ended Sep 30, 2026, above the -$0.09 estimate, a 44.44% surprise.

    What EPS do analysts expect from BEAT next quarter?

    The consensus EPS estimate for Heartbeam for the quarter ending Dec 31, 2026 is -$0.09 from 5 analysts, with estimates from -$0.10 to -$0.08.

    How often does BEAT beat earnings estimates?

    Heartbeam beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -35.17%.